Protein–protein interactions (PPIs) play pivotal roles in the processes of life, including signal transduction, growth, and cell differentiation. There are thought to be more than 600,000 distinct PPIs in humans, and aberrant PPIs are associated with cancer, autoimmune conditions and neurodegenerative diseases. PPIs represent a fast–emerging class of drug targets, with multiple drugs approved or in late-stage clinical development. However, the enormous potential of this field is limited by a poor understanding of the complex, dynamic nature of protein interactions due to ineffective analytical techniques.
MAGNA™ is a versatile platform for analyzing protein-protein interactions with a straightforward and scalable assay. It has clear benefits over existing single molecule approaches which are either unable to detect low force interactions (for example, atomic force microscopy) or lack scalability (optical tweezers).